Warner Chilcott — Merger or Acquisition (June 2013)
50 slides from Warner Chilcott's merger presentation, Jun 3, 2013
Slide 1: Creating a Global Specialty Pharmaceutical Leader
Employee Town Hall Meetings Creating a Global Specialty Pharmaceutical Leader June 2013
Slide 2: Paul Bisaro, President & CEO
Paul Bisaro President & CEO Ww. Actavis
Slide 3: Important Information For Investors And Shareholders
Important Information For Investors And Shareholders This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. New Actavis will file with the Securities and Exchange Commission (the “SEC”) a registration s
Slide 4: Actavis Cautionary Statement Regarding Forward-Looking Statements
Actavis Cautionary Statement Regarding Forward-Looking Statements Statements contained in this communication that refer to Actavis’ estimated or anticipated future results or other non-historical facts are forward-looking statements that reflect Actavis’ current perspective of existing trends and in
Slide 5: Warner Chilcott Cautionary Statement Regarding Forward-Looking Statements
Warner Chilcott Cautionary Statement Regarding Forward-Looking Statements This communication contains forward-looking statements, including statements concerning the proposed transaction with Actavis, our industry, our operations, our anticipated financial performance and financial condition and our
Slide 6: Creating an ~$11 Billion Global Pharmaceutical Company
Creating an ~$11 Billion Global Pharmaceutical Company Creating a ~$3 Billion Specialty Brand Pharmaceutical Company
Slide 7: Proposed Transaction Terms
Proposed Transaction Terms Stock-for-Stock Transaction Anticipate close by end of 2013, subject to shareholder and regulatory approvals Actavis Management to lead combined Company
Slide 8: Achieving a Top Position
Achieving a Top 3 Position US Specialty Sales, $ Billions Teva 5.9 Forest 4.3 Combined Co 2.9 Allergan 2.5 Warner Chilcott 2.4 Valeant 2.0 Endo 1.7 Mylan 0.8 Salix 0.7 Jazz 0.5 Actavis 0.5 Source: Goldman Sachs Analysis Strong Growth Potential Approximately $3 billion Actavis Specialty Brands 2013 p
Slide 9: News coverage of Actavis agreeing to buy Warner Chilcott
"eat UNERADO IGN Ae ee EES eat fei itis eee a | BUSINESS Actavis agrees Warner Chilcott : deal —_ : Last updated 1 hour ago Yahoo to buy nai profits at 9 US drugs maker Actavis, itself the Tumblr for $1.1bn, fie high ‘Warner Chill r ‘subject of bid speculation, is to R sc buy Dublin-based Warner Chi
Slide 10: Media Reports on Proposed Acquisition
Media Reports on Proposed Acquisition “The deal also would help Actavis… further diversify into patented, brand-name drugs. Dow Jones News Service “We believe that the deal makes sense and the paring of the two would be an excellent fit.” David Maris, BMO Capital Markets “The deal will expand Actavi
Slide 11: Key Analyst Reaction to Announcement
Key Analyst Reaction to Announcement We believe Warner Chilcott would address a number of strategic priorities for Actavis and would be highly accretive to Actavis earnings. We believe the WCRX deal makes sense, allowing ACT to enhance its brands business and strengthen its platform, with the therap
Slide 12: Key Analyst Reaction to Announcement
Key Analyst Reaction to Announcement Through its acquisition of Warner Chilcott, Actavis continues its transformation from a U.S.-centric generic drug manufacturer to a major global specialty pharma player. We see little debate around near-term merits of the proposed deal, including low tax structur
Slide 13: About Actavis
About Actavis In late 2012, Watson completed the acquisition of Swiss-based Actavis Group. The combination united two growing, successful and profitable companies into a strong global pharmaceutical player operating in 62+ countries and serving 5+ billion potential consumers.
Slide 14: Actavis by the Numbers
Actavis by the Numbers 3rd largest global generics Truly diverse footprint in 62+ company Countries Strong position in generic oncology injectables 10% market share in Broad product line U.S. Strong semi-solids and 32 manufacturing facilities; liquids capability ~ 44 billion unit capacity 18 global
Slide 15: Actavis Corporate Culture—Our Winning Way
Actavis Corporate Culture—Our Winning Way Learn More at www.OurWinningWay.com
Slide 16: Commitment to Corporate Responsibility
Commitment to Corporate Responsibility
Slide 17: Executive Leadership Team
Executive Leadership Team Sigurdur Fred Bob David Todd Joyce Charles Patrick Olafsson Wilkinson Stewart Buchen Chief Mayr Eagan President, President, President, Chief Legal Financial Chief Chief Human Actavis Actavis Global Officer – Officer – Comms Resources Pharma Specialty Operations Global Globa
Slide 18: Actavis Named to Fortune 500
Actavis Named to Fortune 500 May 6, 2013: Actavis, Inc. named to the Fortune 500 First time in Company history Debut ranking #432 with $5.9B total 2012 revenue List compiled and published annually by Fortune magazine Ranks top 500 U.S. Corporations based on revenue
Slide 19: Actavis: A Specialty Pharmaceutical Company
Actavis A Specialty Pharmaceutical Company Actavis Pharma • Generics, Branded Generics, OTC, Injectables/Hospital Products • Medis (Third-Party Business) Actavis Specialty Brands Women’s Health & Urology • Biosimilars Actavis Global Operations Industry-leading Supply Chain High Quality & Customer Se
Slide 20: Siggi Olafsson, President, Actavis Pharma
Siggi Olafsson President, Actavis Pharma
Slide 21: Strong Global Commercial Position
Strong Global Commercial Position Operations in 62 Countries Serving More Than 5 Billion Potential Customers
Slide 22: Actavis Pharma: Principal Regions
Actavis Pharma: Principal Regions Actavis Pharma Americas Europe MEAAP U.S. Europe Middle East, Africa, Canada CIS, Russia, Turkey Asia Pacific (Incl. Japan, Latin America Medis New Zealand, Australia)
Slide 23: Actavis Pharma: Strong Geographic Diversification
Actavis Pharma: Strong Geographic Diversification Top 10 Markets 2012 Proforma Net Revenue of $6.6 Billion UK Other Markets 13% ROW 38% (~50 countries) Nordics Cluster 8% 31% 8% France 7% US 62% Russia 13% 1% 7% Medis (Third-Party) 3% 6% 3% Australia Greece Canada Bulgaria Germany 2012
Slide 24: Actavis Pharma: 2012—An Impressive Year
Actavis Pharma: 2012—An Impressive Year Double digit sales growth #1 among top 5 Gx companies for sales and unit growth (per IMS) Achieved 20% sales growth in Europe Record number of filings and launches Delivered on key US approvals and launches (Gx Adderall® XR, Gx Xopenex®, Gx Lidoderm® approval)
Slide 25: Actavis U.S. Generics Team Claims Number 1 in Revenues
Actavis U.S. Generics Team Claims Number 1 in Revenues Based on Q1 ‘13 Financial Results • Actavis achieves top spot in its first quarter following last year’s acquisition • Sales totaled $925 million in the 2 largest generic market in the world • Exceeded Teva by $30M 3—Mylan by $200M - Sandoz by $
Slide 26: Actavis Pharma: U.S. Generics Business
Actavis Pharma: U.S. Generics Business Number of Products 190+ Rx product families 61 product families in #1 market position 59 product families in #2 market position 160+ OTC product families Types of Products Rx & OTC Controlled & non controlled substances (Narcotics) Oral Solids (immediate & sust
Slide 27: Target Recognizes Actavis with 2012 Partner Award of Excellence
Target Recognizes Actavis with 2012 Partner Award of Excellence Award recognized legacy Watson U.S. Generics team as a partner of choice in 2012 Presentation noted team’s industry-leading service levels and support; fast and smart delivery of products; and steadfast ability to deliver on our promise
Slide 28: Actavis Global R&D Capabilities and Assets
Actavis Global R&D Capabilities and Assets IR Oral Solids MR Oral Solids Patch/Topicals Injectables Others • India • Florida, USA • Utah, USA • Italy • Lotus BE and CE • Iceland • New Jersey, USA • Maryland, USA • Romania studies, India • Bulgaria • Bulgaria • Inhalation/new technologies, UK • Indon
Slide 29: Impressive R&D Activity in 2012
Impressive R&D Activity in 2012 16+ R&D Centers of Excellence Enhanced capabilities: IR/ER, injectable, semi-solid, oral transmucosal, transdermals 45 ANDAs filed in the US ~185+ applications on file ~1,200 applications pending ~ 250 ongoing R&D projects for EU and US 12 DMFs filed 6 for US, 1 for E
Slide 30: Diversifying US Generics Portfolio into Alternate Dosage Forms
Diversifying US Generics Portfolio into Alternate Dosage Forms In Development In Market Filed at FDA Immediate release oral solids Immediate Immediate release release oral oral solids solids IR Oral Solid Topical Ophthalmic & Optic Transdermal Buccal Other MR Oral Solid Injectable Oral Liquid Inhala
Slide 31: Fred Wilkinson, President, Actavis Specialty Brands
Fred Wilkinson President, Actavis Specialty Brands
Slide 32: Actavis Specialty Brands: Group Overview
Actavis Specialty Brands: Group Overview 40+ U.S. brand products Urology and Women’s Health ~100 scientists in R&D ~430 person U.S. sales team Target Urologists and OB/Gyns 24 person Canada sales team Target Urologists and PCPs
Slide 33: Actavis Specialty Brands: U.S. Brands Business
Actavis Specialty Brands: U.S. Brands Business Therapeutic Categories Benign Prostate Hyperplasia (BPH) Testosterone Replacement Prostate Cancer Over Active Bladder (OAB) Iron Deficiency Contraceptives Infertility Hormone Replacement
Slide 34: Stronger Combined Specialty Brands Portfolio
Stronger Combined Specialty Brands Portfolio Women’s Health Urology GI and Dermatology
Slide 35: Specialty Brands R&D Capabilities and Assets
Specialty Brands R&D Capabilities and Assets Salt Lake City, USA Development Clinical Operations Regulatory Parsippany, NJ • USA Salt Lake City, UT • USA
Slide 36: Combined Small Molecule Pipeline Overview
Combined Small Molecule Pipeline Overview Preclinical Phase I Phase II Phase III NDA Alyssa Crinone® Estelle® Progestin Only Patch Generess® Fe Novel IUD 2nd Generation Novel OC Contraceptive Contraceptive (Global) (U.S.) (Global) (Global) (Canada) Vaginate Vaginal Colvir Vaginal Ring Esmya® Uterine
Slide 37: Bob Stewart, President, Actavis Global Operations
Bob Stewart President, Actavis Global Operations 37 ,
Slide 38: Actavis Industry-Leading Global Supply Chain
Actavis Industry-Leading Global Supply Chain Coleraine • Northern Ireland Hafnarfjordur • Iceland Podolsk • Russia Zoetermeer • The Copiague, NY • USA Netherlands Bucharest • Romania Mississauga, Ontario • Canada Liege • Belgium Dupnitsa • Bulgaria Athens • Greece Salt Lake City, UT • USA Troyan • B
Slide 39: Actavis Global Operations: Manufacturing Capabilities
Actavis Global Operations: Manufacturing Capabilities Manufacturing network ~30 Global Plants Manufacturing capacity ~44 Billion Solid Oral Dosage Units Responsible for producing more than 1,100 generic products and more than 30 branded products Enhanced capabilities in modified release, solid dosag
Slide 40: Anda Incorporated
Anda incorporated
Slide 41: Anda: Overview
Anda: Overview Fourth largest supplier of generic pharmaceuticals in U.S. Established in 1992 to serve pharmacies and physician offices Focused and dedicated telesales model, complemented by progressive technology and outstanding customer service State-of-the-art distribution centers with 10,000+ pr
Slide 42: Paul Bisaro, President & CEO
Paul Bisaro President & CEO Ww. Actavis
Slide 43: Management of Combined Company
Management of Combined Company Paul Bisaro to serve as CEO and President of the combined Company Actavis and Warner Chilcott will both contribute members to the Board of Directors Integration to be managed by Actavis Specialty Brands leadership
Slide 44: Next Steps
Next Steps Approval by shareholders of both companies Successful close subject to customary closing conditions, including the following approvals: Hart-Scott-Rodino in the United States Irish High Court Assuming the successful completion of these reviews, we anticipate closing the transaction by the
Slide 45: Integration Planning Underway
Integration Planning Underway Integration teams will be formed and will work together to assist in the process of combining the two companies Integration planning underway Facilities/operations
Slide 46: Business as Usual Until Closing
Business as Usual Until Closing Employees should operate in a business as usual fashion throughout Actavis and Warner Chilcott Continue to operate as separate companies Continue to meet each company’s separate performance commitments
Slide 47: Commitment to Communications
Commitment to Communications We are committed to keeping you informed throughout the process Key Milestone Updates Updates at Employee Meetings Updates through Employee Memos Updates posted on my.wcrx.com and Actavis’ www.OurWinningWay.com
Slide 48: Creating a Leading Global Specialty Pharmaceutical Company
Creating a Leading Global Specialty Pharmaceutical Company
Slide 49: Statement Required by the Irish Takeover Rules
Statement Required by the Irish Takeover Rules The directors of Warner Chilcott accept responsibility for the information contained in this communication relating to Warner Chilcott and its Associates and the directors of Warner Chilcott and members of their immediate families, related trusts and pe
Slide 50: Dealing Disclosure Requirements
Dealing Disclosure Requirements Under the provisions of Rule 8.3 of the Irish Takeover Panel Act, 1997, Takeover Rules 2007, as amended (the “Irish Takeover Rules”), if any person is, or becomes, ‘interested’ (directly or indirectly) in, 1%, or more of any class of ‘relevant securities’ of Warner Ch